

Tao Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615892/publications.pdf>

Version: 2024-02-01

19
papers

285
citations

1163065

8
h-index

888047

17
g-index

19
all docs

19
docs citations

19
times ranked

545
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. <i>Hepatology</i> , 2019, 70, 1045-1055.	7.3	93
2	Efficacy and safety of direct-acting antiviral-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. <i>Liver International</i> , 2017, 37, 974-981.	3.9	68
3	A Beginning or the End? A Meta-analysis to Assess the Diagnostic Accuracy of Transient Elastography for the Prediction of Esophageal Varices. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 345.	1.1	19
4	Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19. <i>Clinics</i> , 2021, 76, e2604.	1.5	16
5	Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. <i>Journal of Digestive Diseases</i> , 2018, 19, 561-571.	1.5	13
6	Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2017, 23, 5969.	3.3	12
7	Baseline characteristics and changes of biomarkers in disease course predict prognosis of patients with COVID-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 1165-1172.	2.0	12
8	Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 272.	1.1	9
9	Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 740-748.	2.8	8
10	Reply. <i>Hepatology</i> , 2019, 70, 1489-1490.	7.3	5
11	Nucleoside/nucleotide analog consolidation therapy in hepatitis B e antigen positive chronic hepatitis B patients: Three years should be preferred. <i>Hepatology Research</i> , 2021, 51, 633-640.	3.4	5
12	Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. <i>Hepatology Research</i> , 2017, 47, 1000-1007.	3.4	4
13	Performance of quick sequential organ failure assessment (qSOFA) score for prognosis of heat-related hospitalized patients. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 415-419.	1.6	4
14	Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101729.	1.5	4
15	Combination Of Biomarkers In Predicting 28-day Mortality For Septic Patients. <i>Journal of the College of Physicians and Surgeons-Pakistan: JCPSP</i> , 2018, 28, 672-676.	0.4	4
16	Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. <i>World Journal of Gastroenterology</i> , 2021, 27, 1497-1506.	3.3	3
17	Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 30.	1.1	3
18	Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 203-212.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Reply. Hepatology, 2019, 69, 1844-1844.	7.3	1